328 related articles for article (PubMed ID: 18773291)
1. Dystroglycan glycosylation and muscular dystrophy.
Moore CJ; Hewitt JE
Glycoconj J; 2009 Apr; 26(3):349-57. PubMed ID: 18773291
[TBL] [Abstract][Full Text] [Related]
2. Aberrant glycosylation of alpha-dystroglycan and congenital muscular dystrophies.
Endo T
Acta Myol; 2005 Oct; 24(2):64-9. PubMed ID: 16550917
[TBL] [Abstract][Full Text] [Related]
3. Glycosylation defects in muscular dystrophies.
Haliloğlu G; Topaloğlu H
Curr Opin Neurol; 2004 Oct; 17(5):521-7. PubMed ID: 15367856
[TBL] [Abstract][Full Text] [Related]
4. Abnormal glycosylation of dystroglycan in human genetic disease.
Hewitt JE
Biochim Biophys Acta; 2009 Sep; 1792(9):853-61. PubMed ID: 19539754
[TBL] [Abstract][Full Text] [Related]
5. The role of defective glycosylation in congenital muscular dystrophy.
Schachter H; Vajsar J; Zhang W
Glycoconj J; 2004; 20(5):291-300. PubMed ID: 15229394
[TBL] [Abstract][Full Text] [Related]
6. Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.
Manya H; Endo T
Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2462-2472. PubMed ID: 28711406
[TBL] [Abstract][Full Text] [Related]
7. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
[TBL] [Abstract][Full Text] [Related]
8. LARGE glycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy.
Goddeeris MM; Wu B; Venzke D; Yoshida-Moriguchi T; Saito F; Matsumura K; Moore SA; Campbell KP
Nature; 2013 Nov; 503(7474):136-40. PubMed ID: 24132234
[TBL] [Abstract][Full Text] [Related]
9. Glycomarkers for muscular dystrophy.
Hewitt JE
Biochem Soc Trans; 2011 Jan; 39(1):336-9. PubMed ID: 21265799
[TBL] [Abstract][Full Text] [Related]
10. Muscular dystrophies due to defective glycosylation of dystroglycan.
Muntoni F; Brockington M; Godfrey C; Ackroyd M; Robb S; Manzur A; Kinali M; Mercuri E; Kaluarachchi M; Feng L; Jimenez-Mallebrera C; Clement E; Torelli S; Sewry CA; Brown SC
Acta Myol; 2007 Dec; 26(3):129-35. PubMed ID: 18646561
[TBL] [Abstract][Full Text] [Related]
11. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
Toda T
Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
[TBL] [Abstract][Full Text] [Related]
12. Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan.
Stevens E; Carss KJ; Cirak S; Foley AR; Torelli S; Willer T; Tambunan DE; Yau S; Brodd L; Sewry CA; Feng L; Haliloglu G; Orhan D; Dobyns WB; Enns GM; Manning M; Krause A; Salih MA; Walsh CA; Hurles M; Campbell KP; Manzini MC; ; Stemple D; Lin YY; Muntoni F
Am J Hum Genet; 2013 Mar; 92(3):354-65. PubMed ID: 23453667
[TBL] [Abstract][Full Text] [Related]
13. Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.
Yoon JH; Johnson E; Xu R; Martin LT; Martin PT; Montanaro F
J Proteome Res; 2012 Sep; 11(9):4413-24. PubMed ID: 22775139
[TBL] [Abstract][Full Text] [Related]
14. A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan.
Kim J; Lana B; Torelli S; Ryan D; Catapano F; Ala P; Luft C; Stevens E; Konstantinidis E; Louzada S; Fu B; Paredes-Redondo A; Chan AE; Yang F; Stemple DL; Liu P; Ketteler R; Selwood DL; Muntoni F; Lin YY
EMBO Rep; 2019 Nov; 20(11):e47967. PubMed ID: 31566294
[TBL] [Abstract][Full Text] [Related]
15. Increased levels of expression of dystroglycan may protect the heart.
Brancaccio A
Neuromuscul Disord; 2013 Nov; 23(11):867-70. PubMed ID: 23911074
[TBL] [Abstract][Full Text] [Related]
16. Defective glycosylation in muscular dystrophy.
Muntoni F; Brockington M; Blake DJ; Torelli S; Brown SC
Lancet; 2002 Nov; 360(9343):1419-21. PubMed ID: 12424008
[TBL] [Abstract][Full Text] [Related]
17. Disruption of perlecan binding and matrix assembly by post-translational or genetic disruption of dystroglycan function.
Kanagawa M; Michele DE; Satz JS; Barresi R; Kusano H; Sasaki T; Timpl R; Henry MD; Campbell KP
FEBS Lett; 2005 Aug; 579(21):4792-6. PubMed ID: 16098969
[TBL] [Abstract][Full Text] [Related]
18. Congenital muscular dystrophies involving the O-mannose pathway.
Martin PT
Curr Mol Med; 2007 Jun; 7(4):417-25. PubMed ID: 17584082
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage.
Martin PT
Nat Clin Pract Neurol; 2006 Apr; 2(4):222-30. PubMed ID: 16932553
[TBL] [Abstract][Full Text] [Related]
20. Dystroglycan: a possible mediator for reducing congenital muscular dystrophy?
Sciandra F; Gawlik KI; Brancaccio A; Durbeej M
Trends Biotechnol; 2007 Jun; 25(6):262-8. PubMed ID: 17416431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
